Dr. Andrew A. Lukowiak has more than 20 years of leadership experience in the clinical diagnostics market and has served as the Company’s President and Chief Scientific Officer since August 2023. Prior to joining Talis, Dr. Lukowiak served as the President and Chief Scientific Officer of Epigenomics AG, to lead the development of the company’s Next Generation blood-based colorectal cancer screening test. Prior to Epigenomics, Dr. Lukowiak was the Chief Executive Officer of Millennium Health, a leading specialty CLIA laboratory providing toxicology testing services throughout the U.S., where he was brought in after the company’s restructuring in to lead the repositioning and rebranding of the organization. He has also held various senior leadership positions at other molecular diagnostic companies including AltheaDx, GenMark Dx, Hologic, and Third Wave Technologies. Dr. Lukowiak earned a B.S. in Biology from Penn State University and a Ph.D. in Genetics from the University of Georgia.